Cargando…

Optimising the use of mTOR inhibitors in renal transplantation

Renal transplantation is the treatment of choice for end-stage renal failure. Although advances in immunosuppression have led to improvements in short-term outcomes, graft survival beyond 5 to 10 years has not improved. One of the major causes of late renal allograft failure is chronic allograft nep...

Descripción completa

Detalles Bibliográficos
Autor principal:	Russ, Graeme R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834524/ https://www.ncbi.nlm.nih.gov/pubmed/24565283 http://dx.doi.org/10.1186/2047-1440-2-S1-S4

Ejemplares similares

mTOR Inhibitors Induce Erythropoietin Resistance in Renal Transplant Recipients
por: Jefferies, Reece, et al.
Publicado: (2022)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence
por: Klintmalm, Goran B., et al.
Publicado: (2014)

Practical considerations for the use of mTOR inhibitors
por: Diekmann, Fritz, et al.
Publicado: (2015)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors
por: Zaza, Gianluigi, et al.
Publicado: (2013)

The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancy
por: Geissler, Edward K
Publicado: (2013)

The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma
por: Todeschini, Letizia, et al.
Publicado: (2023)

mTOR inhibitors in cancer therapy
por: Xie, Jianling, et al.
Publicado: (2016)

Overview of Research into mTOR Inhibitors
por: Mao, Beibei, et al.
Publicado: (2022)

Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
por: Viana, Sofia D., et al.
Publicado: (2018)

Cancer and mTOR inhibitors in kidney transplantation recipients
por: Kao, Chih-Chin, et al.
Publicado: (2018)

Place of mTOR inhibitors in management of BKV infection after kidney transplantation
por: Jouve, Thomas, et al.
Publicado: (2016)

A Decade of Experience Using mTor Inhibitors in Liver Transplantation
por: Campsen, Jeffrey, et al.
Publicado: (2011)

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

Deptor: not only a mTOR inhibitor
por: Catena, Valeria, et al.
Publicado: (2017)

Role of mTOR Inhibitors in Kidney Disease
por: Kajiwara, Moto, et al.
Publicado: (2016)

Medical Aspects of mTOR Inhibition in Kidney Transplantation
por: Cuadrado-Payán, Elena, et al.
Publicado: (2022)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Clinical development of mTOR inhibitors in breast cancer
por: Vicier, Cecile, et al.
Publicado: (2014)

mTOR Inhibitors in Advanced Biliary Tract Cancers
por: Wu, Chao-En, et al.
Publicado: (2019)

The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis
por: Courtwright, Andrew M., et al.
Publicado: (2017)

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
por: Yuan, RuiRong, et al.
Publicado: (2009)

Inhibitors of mTOR in aging and cancer
por: Zhavoronkov, Alexander
Publicado: (2015)

Gerosuppression by pan-mTOR inhibitors
por: Leontieva, Olga V., et al.
Publicado: (2016)

mTor Inhibitors for the Treatment of Endometriosis
por: Barra, Fabio, et al.
Publicado: (2018)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?
por: Geissler, Edward K
Publicado: (2015)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

Combination of mTOR and MAPK Inhibitors—A Potential Way to Treat Renal Cell Carcinoma
por: Chauhan, Ashutosh, et al.
Publicado: (2016)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

Predicted mechanisms of resistance to mTOR inhibitors
por: Kurmasheva, R T, et al.
Publicado: (2006)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

mTOR inhibitors effects on regulatory T cells and on dendritic cells
por: Stallone, Giovanni, et al.
Publicado: (2016)

Perfect match: mTOR inhibitors and tuberous sclerosis complex
por: Luo, Cong, et al.
Publicado: (2022)

Recent advances and limitations of mTOR inhibitors in the treatment of cancer
por: Ali, Eunus S., et al.
Publicado: (2022)

Playing the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors
por: Pezzicoli, Gaetano, et al.
Publicado: (2021)

mTOR and Tumor Cachexia
por: Duval, Adrian P., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mjshthq0ougo9vsa0m6l8agor6